An FDA advisory committee narrowly voted Thursday to recommend that four peptides, including the wildly popular BPC-157, be made available through compounding pharmacies despite strong objections from the agency’s own career scientists.
The vote is a significant win for Robert F. Kennedy Jr.’s vision of a deregulated health supplement market and a sharp rebuke of the FDA’s institutional risk calculus.
What the Panel Actually Decided
The FDA’s Pharmacy Compounding Advisory Committee voted in favor of adding BPC-157, KPV, TB-500, and MOTS-c to the list of substances that compounding pharmacies can legally produce. The committee convened Thursday and Friday, with three additional peptides, emideltide, epitalon, and semax, evaluated on the second day.
As NPR reported, the votes were narrow, reflecting a genuine split among committee members about whether the potential benefits of broader access outweigh the safety unknowns. The committee’s recommendation is not binding, but it carries significant weight and the current FDA leadership under Kennedy’s influence has shown a clear appetite for loosening restrictions on alternative health products.
The FDA Scientists’ Case Against Approval
Throughout Thursday’s daylong hearing, FDA career scientists presented what amounted to a systematic demolition of the evidence base for these peptides. Their core argument was startling in its simplicity: the agency cannot confidently say what these substances even are at the molecular level.
BPC-157, the most popular of the four, is derived from a protein found in human gastric juice. It has a devoted following among athletes and biohackers who credit it with accelerating injury recovery, reducing inflammation, and improving gut health. But the FDA review found that the published studies are overwhelmingly small, poorly controlled, and conducted on animals rather than humans. The Washington Post reported that FDA scientists detailed safety concerns alongside the evidence gaps, warning that compounded peptides lack the quality controls of FDA-approved drugs.
The scientists’ objections went beyond individual peptide profiles. They argued that compounding pharmacies operate under less stringent quality controls than traditional drug manufacturers, which means that even if a peptide is safe in its pure form, the compounded version may contain impurities, incorrect dosages, or degradation products that introduce their own risks.
The Kennedy Effect
This vote does not happen without Robert F. Kennedy Jr. as Health and Human Services Secretary. Kennedy has made the expansion of alternative health products a signature priority, and his reshaping of FDA advisory panels has been reported by U.S. News as a deliberate strategy to stack committees with members more sympathetic to supplement and compounding industry interests.
The political dynamics are unusually transparent. Traditional drug manufacturers oppose compounding access because it creates a lower-cost alternative to their proprietary products. The compounding industry supports it for the obvious business reasons. Kennedy’s team has framed the issue as one of patient autonomy: Americans should be able to access substances that millions already use, the argument goes, without waiting for a pharmaceutical company to seek FDA approval that may never come because the compounds are not patentable.
The FDA scientists’ counterargument is that the approval process exists precisely because popularity is not evidence of safety. As LNC has covered in other FDA regulatory decisions, the agency’s internal conflicts between career staff and political appointees increasingly play out in public, with patients caught between competing visions of what consumer protection should look like.
What Happens Next
The committee’s recommendation goes to the FDA for a final decision. Under normal circumstances, the agency would weigh the advisory committee’s input against its own staff review and issue a ruling within months. Under Kennedy’s leadership, the timeline could be significantly shorter, and the direction is unlikely to contradict the committee he helped shape.
If the FDA accepts the recommendation, compounding pharmacies across the country could begin producing these peptides within months, creating a multi-billion-dollar market almost overnight. The compounding industry is already preparing for that scenario.
For the millions of Americans already buying BPC-157 and similar peptides through gray-market channels, the practical effect of this vote may be modest. They are already using these substances. The legal change would shift production from unregulated online vendors to licensed compounding pharmacies, which at least provides a floor of quality control even if it falls short of full FDA approval standards.
The larger significance is institutional. This vote marks the first concrete regulatory win for Kennedy’s supplement-expansion agenda, and it establishes a template that could be applied to dozens of other compounds that currently occupy the gray space between supplement and drug. The FDA scientists who testified Thursday made clear that they consider this a dangerous precedent. Whether it is will take years to answer, and the data collection that would provide that answer is exactly the kind of clinical infrastructure that the current administration has shown little interest in funding.